If you feel ill with fever, flu-like symptoms or respiratory illness, please call us to reschedule your appointment. Please Do Not Bring Children Under age 16 to Appointments.

Important Things to Know About Pregnancy and Inflammatory Bowel Disease

By Dr. Christopher Cutler

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the digestive tract that includes Crohn’s disease and ulcerative colitis. Many women worry about how pregnancy can affect their IBD, and more importantly,how treatment for IBD may affect their baby. However, with appropriate treatment and follow up, most women can have a normal pregnancy and deliver a healthy baby.

Fertility
For patients whose IBD is in remission, the chance of becoming pregnant is the same as the general population. However, for patients with active disease, there may be a decrease in fertility. Therefore, women with inflammatory bowel disease should attempt conception at a time when they have no symptoms. Prior extensive abdominal and pelvic surgery may also decrease fertility by scarring the ovaries and fallopian tubes. Certain medications can decrease fertility in men. The use of sulfasalazine in men may cause a reversible decrease in sperm production.

Genetics
Children of parents with IBD are 3-20 times more likely to develop Crohn’s disease or ulcerative colitis than the general population. If the mother has IBD, the risk of passing it on to her child is 4-8%. If both parents have inflammatory bowel disease, the risk can increase to up to 30%.

Disease activity
Two thirds of women with inactive disease at the time of conception remain in remission throughout the pregnancy. However, should a relapse occur, it usually occurs during the first trimester. 70% of patients with active disease at the time of conception have continuous or worsening symptoms throughout the pregnancy. Disease activity in the first pregnancy does not predict problems with future pregnancies.

Birth outcomes
Pregnant women with Crohn’s disease may be at increased risk of having an infant with low birth weight or experiencing premature delivery.

Procedures during pregnancy
Endoscopy during pregnancy should be performed only if there is a strong indication to do so and even then, the procedure should be postponed until the second trimester if possible. However, flexible sigmoidoscopy carries a low risk in any trimester. The data on colonoscopies is limited. Propofol sedation is safe, but should be administered by an anesthesia provider. CAT scans and plain X-rays should be avoided. Ultrasounds and MRIs (without contrast) can be safely performed during pregnancy.

IBD medications during pregnancy

  1. Sulfasalazine – Use is safe during pregnancy but women should be sure to also take folic acid 2 mg daily. Sulfasalazine use in men may cause a decreased sperm production. Therefore, men should stop sulfasalazine and start a 5-ASA medication 4-6 months before planned conception.

5-ASA medications – These medications are generally safe during pregnancy. However, the enteric coating on Asacol and Asacol-HD may be harmful to the fetus, and thus these two 5-ASA medications should not be used by pregnant women as a treatment for IBD.

Steroids – The use of prednisone and budesonide (Entocort or Uceris) overall is safe, but the lowest dose to control symptoms should be used. Use should be avoided during the first trimester due to the risk of oral clefts. Long-term use in the mother may also increase the risk of fetal adrenal insufficiency and low birth weight infants. Women on steroids may also be more likely to develop gestational diabetes and high blood pressure.

Azathioprine (Imuran) and 6-MP – The use of these medications is a bit controversial. They may be associated with preterm birth, but not with birth defects. They should be continued if IBD symptoms can’t be managed with other medications.

Methotrexate – The use of methotrexate is contraindicated in pregnancy. It may cause miscarriages and birth defects. It should be stopped both in men and in women six months prior to planned conception.

Inflimab (Remicade) – The use of biologics in pregnancy is safe. The main concern is transport of the medication throughout the umbilical cord to the baby during the third trimester. This may increase the risk of infection and lead to a suboptimal response to vaccines. Thus, if patients are doing well and their disease is controlled, Remicade should be stopped 8-10 weeks before the estimated due date. Babies should not receive live vaccines for the first six months of life.

Adalimumab (Humira) – This is safe in pregnancy, but like Remicade, it may cross the placenta and thus should be discontinued 4-5 weeks prior to the expected due date.

Vedolizumab (Entyvio) – This is safe in pregnancy, but should also be stopped 8-10 weeks prior to delivery.

Certolizumab (Cimzia) – Unlike the other biologics, there is minimal placental transfer of Cimzia, thus it can be continued throughout the pregnancy.

Metronidazole (Flagyl) – Short courses are probably safe, but not during the first trimester.

Ciprofloxacin (Cipro) – This medication is not recommended during pregnancy due to its effect on growing cartilage.

Lomotil and Imodium – The safety of these medications is controversial, and thus they should be avoided during pregnancy.

Delivery
Most women with IBD can undergo vaginal deliveries. However, women with active perianal disease, active Crohn’s disease of the rectum, and a prior colon resection with ileoanal anastomosis should probably undergo a cesarean section.

Inflammatory bowel disease has implications on fertility, pregnancy, and delivery. Before becoming pregnant, patients with IBD are encouraged to discuss their plans with their gastroenterologist and obstetrician to ensure a safe, healthy pregnancy.

The Future of IBD Treatment

Over a million Americans suffer from Inflammatory Bowel Disease every day. Now, a new drug may be available soon to change the entire face of the disease for those who suffer.

Second Genome, Inc. is a leader in the development of medicines using the bacteria that already exists in the human body. Each human body has a microbiome, comprised of an estimated 100 trillion bacteria. Second Genome is using innovative scientific methods to use these bacteria for IBD treatment and other diseases that are currently under treated in the medical field.

The two most common forms of IBD are Crohn’s disease and ulcerative colitis, both cause the GI tract to swell, making it difficult to digest food, absorb nutrition, and eliminate waste. The new drug, called SGM-1019, was announced in January 2015 as a molecule inhibitor, meaning it identifies and prevents the original driver of IBD through the body’s own microbiome system. If effective, it may have the ability to completely treat IBD safely and effectively with little or no side effects. The drug is delivered orally, and contains a small molecule that may be able to prevent IBD symptoms completely.

“Our scientists have identified a novel and important relationship between microbiome modulation of the target of SGM-1019 and inflammatory bowel disease. SGM-1019 has the potential to address a critical unmet need in inflammatory bowel disease treatment as a safe and well-tolerated oral therapy with an important disease modifying effect,” says Peter DiLaura, President, and CEO of Second Genome.

As of now, the drug is called SGM-1019 and is entering Phase I of a clinical trial. It has already completed a double blind, placebo controlled test, which went well and was successful with no significant adverse events. The next step in the Phase I trial is to explore multiple ascending doses to identify an optimal dose for future studies. Ideally, the Phase I trial should be completed later this year, although it may take much longer for the drug to make it to pharmacy shelves.

The goal of IBD treatment is to improve the quality of life for millions of Americans. Currently, there is no single ideal therapy for the treatment of the disease. However, there are several treatment options, including prescription antibiotics, corticosteroids, Aminosalicylates, and immunomodulators. Still, not every medication works for every patient, and there is no absolute cure. Second Genome’s platform is based in microbiome science, aiming to transform lives with medicines developed through this innovative science to treat multiple diseases where needs are currently not being met.

The genius of Second Genome’s proprietary Microbiome Discovery Platform is the ability to explain the complex relationship between the microbiome and the human body. Once this relationship is explored, Second Genome can isolate and identify more microbiome modulated drug targets. Second Genome obtained exclusive rights to SGM-1019 from an undisclosed biopharmaceutical partner.

At Granite Peaks we can treat your IBD conditions.

Site of Inflammatory Bowel Disease Crucial

At Granite Peaks Gastroenterology, we keep up with current literature.  We thought our patients would find this article interesting regarding recent research on inflammatory bowel disease. 

Continue reading “Site of Inflammatory Bowel Disease Crucial”

Granite Peaks Welcomes James M. Stewart, MD

James M. Stewart, MD:  “As a gastroenterologist, I believe that gastrointestinal health and well-being are critical to enjoying a healthy lifestyle, and all that Utah has to offer. After completing my gastroenterology training at Banner Good Samaritan/ VA program in Phoenix, Arizona, I am pleased to start practicing at Granite Peaks Gastroenterology in Sandy, Utah and will be serving patients from across the Wasatch Front. My special interests include colorectal cancer prevention, GERD, Inflammatory Bowel Disease, and I’ve done research in obesity-related liver disease and other gastrointestinal cancers. After losing family to gastrointestinal cancers, I am dedicated to promoting screenings for early detection of colorectal and esophageal cancer.”

James M. Stewart, MD will be accepting new patients and provides same and next day availability. Stewart sees patients in our Sandy office, and has procedure time every week. Visit Dr. Stewart’s bio on our Meet the Team page by clicking here.

Fellowship: Gastroenterology, Banner Good Samaritan/ VA Hospital-Phoenix, AZ
Residency: Internal Medicine, University of California, San Diego, CA
Internship: Internal Medicine, Residency Program, University of California, San Diego, CA
Doctor of Medicine: University of Utah, Salt Lake City, UT

 

Close Menu